Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead Sciences is answering that challenge with Trodelvy.
Global pharma giant Sanofi and Chinese company Innovent Biologics have penned a strategic partnership to develop and commercialize innovative treatments for patients with hard-to-treat cancers in China.
Chinese vaccine firm CanSino Biologic’s inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac’s shot, but the antibody level dropped in months, clinical trial data showed.
Western nations are working to lessen dependence on China as a supplier for ingredients and goods of all kinds, and China’s economy slowed significantly as a consequence of COVID-19 lockdowns, yet its biopharma sector appears strong. That’s because biotech is designated as a strategic emerging industry.
China will pay close attention to variants of coronavirus in the long term, focusing on their transmission capability, pathogenicity and ability to evade immunity, a Chinese disease control official said on Thursday.
Could WuXi AppTec and Pfizer-backed CStone Pharmaceuticals be snapped up by a larger pharma company? Rumors are circulating that executives with the China-based company are exploring strategic options that could include a sale of the company.
Multiple Chinese cities are adopting fresh COVID-19 curbs, from business halts to lockdowns, to rein in new infections, with the commercial hub of Shanghai bracing for another mass testing effort after finding a highly-transmissible Omicron subvariant.
Wuxi Biologics, a Chinese company that makes ingredients for AstraZeneca’s COVID-19 vaccine, may be a step closer to being taken off a U.S. trade list that it landed on five months ago, wiping HK$77 billion ($9.9 billion) off its market value at the time.
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe, and a positive clinical trial update.
The World Health Organization said on Thursday its latest investigation into the origins of COVID-19 was inconclusive, largely because data from China is missing, another blow to the WHO’s years-long effort to determine how the pandemic began.